<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Diabetes Medications Study Guide - The Nursing Collective</title>
    <meta name="description" content="Comprehensive nursing pharmacology guide for diabetes medications. Master insulin types, oral antidiabetics, GLP-1 agonists, SGLT2 inhibitors, and critical nursing considerations for safe glucose management.">

    <!-- Favicon -->
    <link rel="icon" type="image/x-icon" href="../favicon.ico">

    <!-- Fonts -->
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Outfit:wght@300;400;500;600;700&family=Source+Sans+3:wght@300;400;500;600;700&display=swap" rel="stylesheet">

    <!-- Font Awesome -->
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css" integrity="sha512-iecdLmaskl7CVkqkXNQ/ZH/XLlvWZOJyj7Yy7tcenmpD1ypASozpmT/E0iPtmFIB46ZmdtAc9eNBvH0H/ZpiBw==" crossorigin="anonymous" referrerpolicy="no-referrer">

    <style>
        /* ============================================
           DIABETES MEDICATIONS - PHARMACOLOGY GUIDE
           Reference Card Layout
           ============================================ */

        :root {
            --primary-color: #3B82F6;
            --primary-dark: #2563EB;
            --secondary-color: #EF4444;
            --accent-color: #60A5FA;
            --text-primary: #1f2937;
            --text-secondary: #4b5563;
            --background: #ffffff;
            --border-color: #e5e7eb;
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: 'Source Sans 3', -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
            line-height: 1.7;
            color: var(--text-primary);
            background: #f3f4f6;
        }

        /* Download Bar - Fixed at top */
        .download-bar {
            position: fixed;
            top: 0;
            left: 0;
            right: 0;
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            padding: 12px 24px;
            display: flex;
            justify-content: space-between;
            align-items: center;
            z-index: 1000;
            box-shadow: 0 2px 10px rgba(0,0,0,0.2);
        }

        .download-bar-brand {
            display: flex;
            align-items: center;
            gap: 12px;
            font-weight: 600;
        }

        .download-bar-brand img {
            height: 32px;
            width: auto;
        }

        .download-bar-actions {
            display: flex;
            gap: 12px;
        }

        .btn-download {
            display: inline-flex;
            align-items: center;
            gap: 8px;
            padding: 10px 20px;
            background: white;
            color: var(--primary-color);
            border: none;
            border-radius: 8px;
            font-weight: 600;
            font-size: 0.95rem;
            cursor: pointer;
            transition: all 0.2s ease;
            text-decoration: none;
        }

        .btn-download:hover {
            background: #eff6ff;
            transform: translateY(-1px);
        }

        .btn-back {
            display: inline-flex;
            align-items: center;
            gap: 8px;
            padding: 10px 20px;
            background: rgba(255,255,255,0.15);
            color: white;
            border: 1px solid rgba(255,255,255,0.3);
            border-radius: 8px;
            font-weight: 500;
            font-size: 0.95rem;
            cursor: pointer;
            transition: all 0.2s ease;
            text-decoration: none;
        }

        .btn-back:hover {
            background: rgba(255,255,255,0.25);
        }

        /* Document Container */
        .document-container {
            max-width: 850px;
            margin: 80px auto 40px;
            background: white;
            box-shadow: 0 4px 20px rgba(0,0,0,0.15);
        }

        /* Cover Page - Blue/red matching glucometer icon */
        .cover-page {
            background: linear-gradient(135deg, #2563EB 0%, #3B82F6 40%, #60A5FA 100%);
            color: white;
            padding: 80px 60px;
            text-align: center;
            position: relative;
            overflow: hidden;
        }

        .cover-page::before {
            content: '';
            position: absolute;
            top: 0;
            left: 0;
            right: 0;
            bottom: 0;
            background: url("data:image/svg+xml,%3Csvg width='60' height='60' viewBox='0 0 60 60' xmlns='http://www.w3.org/2000/svg'%3E%3Cg fill='none' fill-rule='evenodd'%3E%3Cg fill='%23ffffff' fill-opacity='0.05'%3E%3Cpath d='M36 34v-4h-2v4h-4v2h4v4h2v-4h4v-2h-4zm0-30V0h-2v4h-4v2h4v4h2V6h4V4h-4zM6 34v-4H4v4H0v2h4v4h2v-4h4v-2H6zM6 4V0H4v4H0v2h4v4h2V6h4V4H6z'/%3E%3C/g%3E%3C/g%3E%3C/svg%3E");
            opacity: 0.5;
        }

        .cover-content {
            position: relative;
            z-index: 1;
        }

        .cover-logo {
            width: 80px;
            height: 80px;
            background: white;
            border-radius: 20px;
            display: flex;
            align-items: center;
            justify-content: center;
            margin: 0 auto 30px;
            box-shadow: 0 4px 15px rgba(0,0,0,0.2);
            padding: 12px;
        }

        .cover-logo img {
            width: 100%;
            height: 100%;
            object-fit: contain;
        }

        .cover-category {
            display: inline-block;
            padding: 8px 24px;
            background: rgba(255,255,255,0.2);
            border-radius: 50px;
            font-size: 0.9rem;
            font-weight: 600;
            letter-spacing: 1px;
            text-transform: uppercase;
            margin-bottom: 24px;
        }

        .cover-title {
            font-family: 'Outfit', sans-serif;
            font-size: 3.5rem;
            font-weight: 700;
            margin-bottom: 20px;
            line-height: 1.1;
        }

        .cover-subtitle {
            font-size: 1.2rem;
            opacity: 0.95;
            max-width: 600px;
            margin: 0 auto 40px;
            line-height: 1.6;
        }

        .cover-meta {
            display: flex;
            justify-content: center;
            gap: 40px;
            flex-wrap: wrap;
            padding-top: 30px;
            border-top: 1px solid rgba(255,255,255,0.2);
        }

        .cover-meta-item {
            text-align: center;
        }

        .cover-meta-item .label {
            font-size: 0.8rem;
            opacity: 0.8;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }

        .cover-meta-item .value {
            font-size: 1.1rem;
            font-weight: 600;
            margin-top: 4px;
        }

        .cover-brand {
            margin-top: 50px;
            padding-top: 30px;
            border-top: 1px solid rgba(255,255,255,0.2);
            font-size: 0.95rem;
            opacity: 0.9;
        }

        /* Document Content */
        .document-content {
            padding: 60px;
        }

        /* Learning Objectives */
        .learning-objectives {
            background: linear-gradient(135deg, #ecfdf5, #d1fae5);
            border: 2px solid #10b981;
            border-radius: 12px;
            padding: 28px;
            margin-bottom: 40px;
        }

        .learning-objectives h2 {
            font-family: 'Outfit', sans-serif;
            font-size: 1.2rem;
            font-weight: 700;
            color: #059669;
            margin-bottom: 16px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .learning-objectives ul {
            list-style: none;
            margin: 0;
            padding: 0;
        }

        .learning-objectives li {
            display: flex;
            align-items: flex-start;
            gap: 12px;
            padding: 8px 0;
            color: var(--text-primary);
            font-size: 1rem;
        }

        .learning-objectives li i {
            color: #10b981;
            margin-top: 4px;
            flex-shrink: 0;
        }

        /* High-Yield Summary */
        .high-yield-summary {
            background: linear-gradient(135deg, #fffbeb, #fef3c7);
            border: 2px solid #f59e0b;
            border-radius: 12px;
            padding: 28px;
            margin-bottom: 40px;
        }

        .high-yield-summary h2 {
            font-family: 'Outfit', sans-serif;
            font-size: 1.2rem;
            font-weight: 700;
            color: #d97706;
            margin-bottom: 8px;
            display: flex;
            align-items: center;
            gap: 10px;
            border-bottom: none;
            padding-bottom: 0;
        }

        .high-yield-subtitle {
            color: var(--text-secondary);
            font-size: 0.95rem;
            margin-bottom: 16px;
        }

        .high-yield-summary ul {
            list-style: none;
            margin: 0;
            padding: 0;
        }

        .high-yield-summary li {
            padding: 8px 0;
            border-bottom: 1px solid rgba(245,158,11,0.15);
            color: var(--text-secondary);
            font-size: 0.98rem;
        }

        .high-yield-summary li:last-child { border-bottom: none; }

        .high-yield-cta {
            margin-top: 16px;
            font-weight: 600;
            color: #d97706;
            font-size: 0.95rem;
        }

        /* Table of Contents */
        .table-of-contents {
            background: #f9fafb;
            border: 1px solid var(--border-color);
            border-radius: 12px;
            padding: 28px;
            margin-bottom: 40px;
        }

        .table-of-contents h2 {
            font-family: 'Outfit', sans-serif;
            font-size: 1.1rem;
            font-weight: 700;
            color: var(--text-primary);
            margin-bottom: 16px;
        }

        .table-of-contents ul {
            list-style: none;
            margin: 0;
            padding: 0;
            columns: 2;
            column-gap: 30px;
        }

        .table-of-contents li {
            break-inside: avoid;
            margin-bottom: 8px;
        }

        .table-of-contents a {
            display: flex;
            align-items: center;
            gap: 10px;
            padding: 8px 12px;
            color: var(--text-secondary);
            text-decoration: none;
            border-radius: 6px;
            font-size: 0.95rem;
            transition: all 0.2s ease;
        }

        .table-of-contents a:hover {
            background: var(--primary-color);
            color: white;
        }

        .toc-number {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 22px;
            height: 22px;
            background: var(--primary-color);
            color: white;
            border-radius: 5px;
            font-size: 0.75rem;
            font-weight: 600;
            flex-shrink: 0;
        }

        .table-of-contents a:hover .toc-number {
            background: white;
            color: var(--primary-color);
        }

        /* Content Sections */
        .guide-section {
            margin-bottom: 50px;
            scroll-margin-top: 80px;
        }

        .guide-section h2 {
            font-family: 'Outfit', sans-serif;
            font-size: 1.6rem;
            font-weight: 700;
            color: var(--text-primary);
            margin-bottom: 20px;
            padding-bottom: 12px;
            border-bottom: 3px solid var(--primary-color);
            display: flex;
            align-items: center;
            gap: 12px;
        }

        .section-icon {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 36px;
            height: 36px;
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            border-radius: 8px;
            font-size: 1rem;
        }

        .guide-section h3 {
            font-family: 'Outfit', sans-serif;
            font-size: 1.25rem;
            font-weight: 600;
            color: var(--text-primary);
            margin: 28px 0 14px;
        }

        .guide-section h4 {
            font-family: 'Outfit', sans-serif;
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--primary-color);
            margin: 20px 0 10px;
        }

        .guide-section p {
            color: var(--text-secondary);
            font-size: 1.02rem;
            margin-bottom: 14px;
        }

        .guide-section ul, .guide-section ol {
            color: var(--text-secondary);
            margin-bottom: 16px;
            padding-left: 24px;
        }

        .guide-section li {
            margin-bottom: 8px;
        }

        .guide-section strong {
            color: var(--text-primary);
        }

        /* Info Boxes */
        .info-box {
            border-radius: 10px;
            padding: 18px 22px;
            margin: 20px 0;
            border-left: 4px solid;
        }

        .info-box.clinical-pearl {
            background: linear-gradient(135deg, #fffbeb, #fef3c7);
            border-color: #f59e0b;
        }

        .info-box.warning {
            background: #fef2f2;
            border-color: #ef4444;
        }

        .info-box.tip {
            background: #ecfdf5;
            border-color: #10b981;
        }

        .info-box.nclex-tip {
            background: #f5f3ff;
            border-color: #8b5cf6;
        }

        .info-box.mnemonic {
            background: #fffbeb;
            border-color: #f59e0b;
        }

        .info-box.pediatric {
            background: linear-gradient(135deg, #fdf2f8 0%, #fce7f3 100%);
            border-color: #ec4899;
        }

        .info-box-header {
            display: flex;
            align-items: center;
            gap: 8px;
            font-weight: 700;
            margin-bottom: 10px;
            font-size: 0.95rem;
        }

        .info-box.clinical-pearl .info-box-header { color: #d97706; }
        .info-box.warning .info-box-header { color: #ef4444; }
        .info-box.tip .info-box-header { color: #059669; }
        .info-box.nclex-tip .info-box-header { color: #7c3aed; }
        .info-box.mnemonic .info-box-header { color: #d97706; }
        .info-box.pediatric .info-box-header { color: #db2777; }

        .info-box p { margin: 0; color: var(--text-secondary); font-size: 0.98rem; }
        .info-box ul { margin: 8px 0 0; padding-left: 18px; }
        .info-box li { margin-bottom: 4px; font-size: 0.98rem; }

        /* Tables */
        .guide-table-wrapper {
            overflow-x: auto;
            margin: 20px 0;
            border-radius: 10px;
            border: 1px solid var(--border-color);
        }

        .guide-table {
            width: 100%;
            border-collapse: collapse;
            font-size: 0.92rem;
        }

        .guide-table thead {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
        }

        .guide-table th {
            padding: 12px 14px;
            text-align: left;
            font-weight: 600;
        }

        .guide-table tbody tr {
            border-bottom: 1px solid var(--border-color);
        }

        .guide-table tbody tr:hover {
            background: #f9fafb;
        }

        .guide-table td {
            padding: 12px 14px;
            color: var(--text-secondary);
        }

        .guide-table td:first-child {
            font-weight: 600;
            color: var(--text-primary);
        }

        /* Comparison Cards */
        .comparison-grid {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 20px;
            margin: 20px 0;
        }

        .comparison-card {
            border-radius: 12px;
            border: 2px solid var(--border-color);
            overflow: hidden;
        }

        .comparison-card-header {
            padding: 16px;
            text-align: center;
            font-weight: 700;
            font-size: 1.05rem;
            color: white;
        }

        .comparison-card.type1 .comparison-card-header {
            background: linear-gradient(135deg, #3b82f6, #2563eb);
        }

        .comparison-card.type2 .comparison-card-header {
            background: linear-gradient(135deg, #f59e0b, #d97706);
        }

        .comparison-card.rapid .comparison-card-header {
            background: linear-gradient(135deg, #ef4444, #dc2626);
        }

        .comparison-card.long .comparison-card-header {
            background: linear-gradient(135deg, #10b981, #059669);
        }

        .comparison-card-body {
            padding: 18px;
        }

        .comparison-card-body h4 {
            font-size: 0.95rem;
            margin: 0 0 10px;
        }

        .comparison-card-body ul {
            list-style: none;
            padding: 0;
            margin: 0 0 14px;
        }

        .comparison-card-body li {
            display: flex;
            align-items: flex-start;
            gap: 8px;
            padding: 6px 0;
            color: var(--text-secondary);
            font-size: 0.9rem;
            border-bottom: 1px solid var(--border-color);
        }

        .comparison-card-body li:last-child { border-bottom: none; }
        .comparison-card-body li i { color: var(--primary-color); margin-top: 3px; flex-shrink: 0; }

        /* Interventions List */
        .interventions-list {
            background: #f9fafb;
            border-radius: 12px;
            padding: 22px;
            margin: 20px 0;
        }

        .interventions-list h4 {
            font-family: 'Outfit', sans-serif;
            font-size: 1rem;
            margin: 0 0 14px;
            display: flex;
            align-items: center;
            gap: 8px;
        }

        .interventions-list h4 i { color: var(--primary-color); }

        .intervention-item {
            display: flex;
            gap: 14px;
            padding: 14px;
            background: white;
            border-radius: 10px;
            margin-bottom: 10px;
            border: 1px solid var(--border-color);
        }

        .intervention-number {
            display: flex;
            align-items: center;
            justify-content: center;
            width: 32px;
            height: 32px;
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            border-radius: 8px;
            font-weight: 700;
            font-size: 0.9rem;
            flex-shrink: 0;
        }

        .intervention-content h5 {
            font-size: 0.95rem;
            font-weight: 600;
            color: var(--text-primary);
            margin: 0 0 4px;
        }

        .intervention-content p {
            font-size: 0.9rem;
            color: var(--text-secondary);
            margin: 0;
        }

        /* Quick Reference */
        .quick-reference {
            background: white;
            border: 2px solid var(--primary-color);
            border-radius: 12px;
            padding: 20px;
            margin: 24px 0;
        }

        .quick-reference h3 {
            font-size: 1.1rem;
            color: var(--primary-color);
            margin: 0 0 14px;
            display: flex;
            align-items: center;
            gap: 8px;
        }

        .quick-reference-grid {
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 12px;
        }

        .quick-ref-item {
            background: #f9fafb;
            padding: 12px;
            border-radius: 8px;
        }

        .quick-ref-item .label {
            font-size: 0.8rem;
            color: var(--text-secondary);
            margin-bottom: 2px;
        }

        .quick-ref-item .value {
            font-size: 1rem;
            font-weight: 600;
            color: var(--text-primary);
        }

        /* Bottom Line */
        .bottom-line {
            background: linear-gradient(135deg, #eff6ff, #dbeafe);
            border: 1px solid #93c5fd;
            border-radius: 10px;
            padding: 16px 20px;
            margin: 24px 0;
            font-size: 0.95rem;
            color: var(--text-primary);
        }

        /* FlorenceBot Tips */
        .florencebot-tip {
            background: linear-gradient(135deg, #f5f3ff, #ede9fe);
            border-left: 4px solid #8b5cf6;
            border-radius: 10px;
            padding: 20px;
            margin: 20px 0;
        }

        .florencebot-tip-header {
            display: flex;
            align-items: center;
            gap: 10px;
            margin-bottom: 8px;
        }

        .florencebot-tip-icon {
            width: 28px;
            height: 28px;
            background: linear-gradient(135deg, #8b5cf6, #7c3aed);
            border-radius: 6px;
            display: flex;
            align-items: center;
            justify-content: center;
            color: white;
            font-size: 0.8rem;
        }

        .florencebot-tip-label {
            font-size: 0.8rem;
            font-weight: 700;
            color: #7c3aed;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }

        .florencebot-tip-title {
            font-family: 'Outfit', sans-serif;
            font-size: 1.05rem;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 8px;
        }

        .florencebot-tip-content {
            color: var(--text-secondary);
            font-size: 0.95rem;
            line-height: 1.6;
        }

        /* Key Points Summary */
        .key-points-summary {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            border-radius: 12px;
            padding: 28px;
            margin: 40px 0 0;
            color: white;
        }

        .key-points-summary h2 {
            font-family: 'Outfit', sans-serif;
            font-size: 1.3rem;
            margin: 0 0 18px;
            display: flex;
            align-items: center;
            gap: 10px;
            color: white;
            border-bottom: none;
            padding-bottom: 0;
        }

        .key-points-grid {
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 14px;
        }

        .key-point {
            background: rgba(255,255,255,0.15);
            padding: 14px;
            border-radius: 10px;
            display: flex;
            align-items: flex-start;
            gap: 10px;
        }

        .key-point i { font-size: 1.1rem; margin-top: 2px; }
        .key-point p { margin: 0; font-size: 0.92rem; line-height: 1.4; }

        /* Cross References */
        .cross-references {
            background: #ecfdf5;
            border: 2px solid #10b981;
            border-radius: 12px;
            padding: 28px;
            margin-top: 30px;
        }

        .cross-references h2 {
            color: #059669;
            border-bottom: none;
            padding-bottom: 0;
            font-size: 1.2rem;
        }

        .cross-ref-group {
            margin-bottom: 16px;
        }

        .cross-ref-group:last-child { margin-bottom: 0; }

        .cross-ref-group h3 {
            font-size: 0.95rem;
            color: var(--text-secondary);
            margin: 0 0 8px;
        }

        .cross-ref-group ul {
            list-style: none;
            margin: 0;
            padding: 0;
        }

        .cross-ref-group li {
            margin-bottom: 4px;
        }

        .cross-ref-group a {
            color: #059669;
            text-decoration: none;
            font-weight: 500;
            display: flex;
            align-items: center;
            gap: 8px;
            padding: 4px 0;
        }

        .cross-ref-group a:hover { text-decoration: underline; }

        .coming-soon {
            color: var(--text-secondary);
            font-style: italic;
            display: flex;
            align-items: center;
            gap: 8px;
            padding: 4px 0;
        }

        /* Footer */
        .document-footer {
            text-align: center;
            padding: 32px 48px;
            border-top: 1px solid var(--border-color);
            background: linear-gradient(135deg, #f8fafc, #f1f5f9);
        }

        .footer-logo {
            height: 48px;
            width: auto;
            margin-bottom: 12px;
        }

        .footer-tagline {
            font-size: 0.9rem;
            color: var(--text-secondary);
            margin-bottom: 16px;
        }

        .footer-copyright {
            font-size: 0.85rem;
            color: var(--text-secondary);
        }

        /* Practice Questions */
        .practice-questions h2 {
            font-family: 'Outfit', sans-serif;
            font-size: 1.3rem;
            font-weight: 700;
            color: var(--text-primary);
            margin-bottom: 20px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .quiz-cta-box {
            display: flex;
            align-items: center;
            gap: 24px;
            background: linear-gradient(135deg, #eff6ff, #dbeafe);
            border: 2px solid #3b82f6;
            border-radius: 14px;
            padding: 24px;
        }

        .quiz-cta-icon {
            width: 60px;
            height: 60px;
            background: linear-gradient(135deg, #3b82f6, #2563eb);
            border-radius: 14px;
            display: flex;
            align-items: center;
            justify-content: center;
            color: white;
            font-size: 1.5rem;
            flex-shrink: 0;
        }

        .quiz-cta-content { flex: 1; }
        .quiz-cta-content h3 { font-family: 'Outfit', sans-serif; font-size: 1.1rem; margin: 0 0 6px; }
        .quiz-cta-content p { font-size: 0.9rem; color: var(--text-secondary); margin: 0 0 10px; }

        .quiz-cta-stats {
            display: flex;
            gap: 16px;
            font-size: 0.85rem;
            color: var(--text-secondary);
        }

        .quiz-cta-stats span {
            display: flex;
            align-items: center;
            gap: 5px;
        }

        .quiz-cta-button {
            display: inline-flex;
            align-items: center;
            gap: 8px;
            padding: 12px 24px;
            background: linear-gradient(135deg, #3b82f6, #2563eb);
            color: white;
            border: none;
            border-radius: 10px;
            font-weight: 600;
            font-size: 1rem;
            text-decoration: none;
            white-space: nowrap;
            transition: all 0.2s ease;
        }

        .quiz-cta-button:hover {
            transform: translateY(-2px);
            box-shadow: 0 4px 12px rgba(59,130,246,0.4);
        }

        /* Print Styles */
        @page {
            margin: 0.6in 0.4in;
        }

        @media print {
            .download-bar { display: none !important; }

            body {
                background: white !important;
                margin: 0 !important;
                padding: 0 !important;
            }

            .document-container {
                margin: 0 !important;
                box-shadow: none !important;
                max-width: 100% !important;
                width: 100% !important;
            }

            * {
                -webkit-print-color-adjust: exact !important;
                print-color-adjust: exact !important;
                color-adjust: exact !important;
            }

            .cover-page {
                page-break-after: always;
                break-after: page;
            }

            .info-box { page-break-inside: avoid; break-inside: avoid; }
            .guide-table-wrapper { page-break-inside: avoid; break-inside: avoid; }
            .comparison-card { page-break-inside: avoid; break-inside: avoid; }
            .intervention-item { page-break-inside: avoid; break-inside: avoid; }
            .quick-reference { page-break-inside: avoid; break-inside: avoid; }
            .learning-objectives { page-break-inside: avoid; break-inside: avoid; }
            .key-points-summary { page-break-inside: avoid; break-inside: avoid; }
            .florencebot-tip { page-break-inside: avoid; break-inside: avoid; }

            h2, h3, h4 {
                page-break-after: avoid;
                break-after: avoid;
            }

            .guide-section h3 + .guide-table-wrapper,
            .guide-section h3 + .info-box,
            .guide-section h3 + .comparison-grid,
            .guide-section h3 + .interventions-list {
                page-break-before: avoid;
                break-before: avoid;
            }

            .comparison-grid { page-break-inside: auto; }
            .interventions-list { page-break-inside: auto; }

            a { text-decoration: underline; }

            .document-footer {
                page-break-inside: avoid;
            }
        }

        /* Responsive */
        @media (max-width: 768px) {
            .download-bar {
                flex-direction: column;
                gap: 12px;
                padding: 12px 16px;
            }
            .download-bar-actions {
                width: 100%;
                justify-content: center;
            }
            .document-container { margin: 120px 10px 20px; }
            .cover-page { padding: 50px 30px; }
            .cover-title { font-size: 2.2rem; }
            .cover-meta { flex-direction: column; gap: 20px; }
            .document-content { padding: 30px 24px; }
            .table-of-contents ul { columns: 1; }
            .comparison-grid { grid-template-columns: 1fr; }
            .quick-reference-grid { grid-template-columns: 1fr; }
            .key-points-grid { grid-template-columns: 1fr; }
            .quiz-cta-box { flex-direction: column; text-align: center; }
        }
    </style>

    <!-- Sidebar Styles (shared across all guides) -->
    <link rel="stylesheet" href="guide-sidebar.css">
</head>
<body data-product-id="diabetes-medications" data-guide-name="Diabetes-Medications">
    <!-- Download Bar -->
    <div class="download-bar">
        <div class="download-bar-brand">
            <i class="fas fa-book-medical"></i>
            <span>The Nursing Collective Study Guide</span>
        </div>
        <div class="download-bar-actions">
            <a href="../dashboard.html" class="btn-back">
                <i class="fas fa-arrow-left"></i> Back to Dashboard
            </a>
            <button class="btn-download" id="download-pdf-btn">
                <i class="fas fa-file-pdf"></i> Save as PDF
            </button>
        </div>
    </div>

    <!-- Document -->
    <div class="document-container">

        <!-- Cover Page -->
        <div class="cover-page">
            <div class="cover-content">
                <div class="cover-logo">
                    <img src="../assets/images/guide-icons/diabetes-medications.webp" alt="Diabetes Medications">
                </div>
                <div class="cover-category">Pharmacology</div>
                <h1 class="cover-title">Diabetes Medications</h1>
                <p class="cover-subtitle">Complete pharmacology reference covering insulin types, oral antidiabetics, injectable agents, mechanisms of action, and critical nursing considerations for safe glucose management.</p>
                <div class="cover-meta">
                    <div class="cover-meta-item">
                        <div class="label">Reading Time</div>
                        <div class="value">20-25 minutes</div>
                    </div>
                    <div class="cover-meta-item">
                        <div class="label">Difficulty Level</div>
                        <div class="value">Intermediate</div>
                    </div>
                    <div class="cover-meta-item">
                        <div class="label">Last Updated</div>
                        <div class="value">February 2026</div>
                    </div>
                </div>
                <div class="cover-brand">
                    <i class="fas fa-graduation-cap"></i> The Nursing Collective
                </div>
            </div>
        </div>

        <!-- Document Content -->
        <div class="document-content">

            <!-- Learning Objectives -->
            <section class="learning-objectives">
                <h2><i class="fas fa-bullseye"></i> Learning Objectives</h2>
                <ul>
                    <li><i class="fas fa-check-circle"></i> Compare onset, peak, and duration of rapid-acting, short-acting, intermediate, and long-acting insulins</li>
                    <li><i class="fas fa-check-circle"></i> Explain the mechanism of action for each oral antidiabetic drug class</li>
                    <li><i class="fas fa-check-circle"></i> Identify critical nursing assessments before and during diabetes medication administration</li>
                    <li><i class="fas fa-check-circle"></i> Recognize signs of hypoglycemia and appropriate nursing interventions</li>
                    <li><i class="fas fa-check-circle"></i> Differentiate medications used in Type 1 versus Type 2 diabetes</li>
                    <li><i class="fas fa-check-circle"></i> Apply patient teaching points for insulin administration and oral agents</li>
                    <li><i class="fas fa-check-circle"></i> Identify contraindications and high-risk drug interactions for each class</li>
                </ul>
            </section>

            <!-- High-Yield Summary -->
            <section class="high-yield-summary" id="high-yield-summary">
                <h2><i class="fas fa-bolt"></i> High-Yield Summary &mdash; Review This in 60 Seconds</h2>
                <p class="high-yield-subtitle">The must-know facts from this guide, distilled for quick review.</p>
                <ul>
                    <li><strong>Type 1 = absolute insulin deficiency</strong> (autoimmune destruction of beta cells). Always requires exogenous insulin. Oral agents alone are NOT sufficient.</li>
                    <li><strong>Type 2 = insulin resistance + relative deficiency.</strong> Managed with lifestyle changes, oral agents, injectables, and eventually insulin as disease progresses.</li>
                    <li><strong>Metformin is first-line for Type 2 diabetes.</strong> Decreases hepatic glucose production. Hold before contrast dye procedures (risk of lactic acidosis). No hypoglycemia when used alone.</li>
                    <li><strong>Insulin timing matters:</strong> Rapid-acting (lispro, aspart) = give with meals. Regular = give 30 min before meals. NPH = give consistently, never IV. Glargine = give once daily at same time, never mix.</li>
                    <li><strong>Sulfonylureas (glipizide, glyburide)</strong> stimulate insulin release from the pancreas. They DO cause hypoglycemia and weight gain.</li>
                    <li><strong>GLP-1 agonists (-tide drugs: semaglutide, liraglutide)</strong> enhance insulin secretion, slow gastric emptying, promote weight loss. Black box warning for thyroid C-cell tumors.</li>
                    <li><strong>SGLT2 inhibitors (-gliflozin drugs: empagliflozin, dapagliflozin)</strong> block glucose reabsorption in kidneys. Watch for UTIs, genital infections, and euglycemic DKA.</li>
                    <li><strong>Rule of 15 for hypoglycemia:</strong> Give 15g fast-acting carbs, recheck BG in 15 minutes, repeat if still below 70 mg/dL.</li>
                    <li><strong>Never mix glargine (Lantus) or detemir (Levemir)</strong> with other insulins. NPH is the only insulin that is cloudy (roll, don't shake).</li>
                    <li><strong>When mixing insulins:</strong> Draw up clear (Regular) before cloudy (NPH). Memory aid: "RN" = Regular before NPH.</li>
                </ul>
                <p class="high-yield-cta">Want the full breakdown? Keep reading below.</p>
            </section>

            <!-- Table of Contents -->
            <nav class="table-of-contents">
                <h2><i class="fas fa-list"></i> Table of Contents</h2>
                <ul>
                    <li><a href="#overview"><span class="toc-number">1</span> Diabetes Overview & Drug Therapy Goals</a></li>
                    <li><a href="#insulin-types"><span class="toc-number">2</span> Insulin Types & Administration</a></li>
                    <li><a href="#metformin"><span class="toc-number">3</span> Metformin (Biguanides)</a></li>
                    <li><a href="#sulfonylureas-meglitinides"><span class="toc-number">4</span> Sulfonylureas & Meglitinides</a></li>
                    <li><a href="#tzds-agi"><span class="toc-number">5</span> TZDs & Alpha-Glucosidase Inhibitors</a></li>
                    <li><a href="#incretin-based"><span class="toc-number">6</span> DPP-4 Inhibitors & GLP-1 Agonists</a></li>
                    <li><a href="#sglt2"><span class="toc-number">7</span> SGLT2 Inhibitors</a></li>
                    <li><a href="#hypoglycemia"><span class="toc-number">8</span> Hypoglycemia Management</a></li>
                    <li><a href="#comparison"><span class="toc-number">9</span> Drug Class Comparison</a></li>
                    <li><a href="#pediatric"><span class="toc-number">10</span> Pediatric Considerations</a></li>
                </ul>
            </nav>

            <!-- ============================================ -->
            <!-- Section 1: Overview -->
            <!-- ============================================ -->
            <section class="guide-section" id="overview">
                <h2><span class="section-icon"><i class="fas fa-book-open"></i></span> Diabetes Overview & Drug Therapy Goals</h2>

                <p>Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Understanding the pathophysiology of Type 1 versus Type 2 diabetes is essential for choosing appropriate pharmacological therapy.</p>

                <div class="comparison-grid">
                    <div class="comparison-card type1">
                        <div class="comparison-card-header">
                            <i class="fas fa-syringe"></i> Type 1 Diabetes
                        </div>
                        <div class="comparison-card-body">
                            <h4>Autoimmune Beta-Cell Destruction</h4>
                            <ul>
                                <li><i class="fas fa-check"></i> <strong>Absolute insulin deficiency</strong></li>
                                <li><i class="fas fa-check"></i> Usually diagnosed in childhood/adolescence</li>
                                <li><i class="fas fa-check"></i> Requires exogenous insulin for survival</li>
                                <li><i class="fas fa-check"></i> Prone to diabetic ketoacidosis (DKA)</li>
                                <li><i class="fas fa-check"></i> Not preventable with lifestyle changes</li>
                            </ul>
                            <h4>Drug Therapy</h4>
                            <p>Insulin only (basal-bolus regimen or insulin pump)</p>
                        </div>
                    </div>

                    <div class="comparison-card type2">
                        <div class="comparison-card-header">
                            <i class="fas fa-pills"></i> Type 2 Diabetes
                        </div>
                        <div class="comparison-card-body">
                            <h4>Insulin Resistance + Relative Deficiency</h4>
                            <ul>
                                <li><i class="fas fa-check"></i> <strong>Cells resist insulin action</strong></li>
                                <li><i class="fas fa-check"></i> Usually diagnosed in adults (rising in youth)</li>
                                <li><i class="fas fa-check"></i> Managed with lifestyle + oral agents + injectables</li>
                                <li><i class="fas fa-check"></i> Prone to hyperglycemic hyperosmolar state (HHS)</li>
                                <li><i class="fas fa-check"></i> Modifiable risk factors: obesity, inactivity</li>
                            </ul>
                            <h4>Drug Therapy</h4>
                            <p>Metformin first-line, then add agents as needed. May require insulin as disease progresses.</p>
                        </div>
                    </div>
                </div>

                <div class="quick-reference">
                    <h3><i class="fas fa-bullseye"></i> Glycemic Targets (ADA Guidelines)</h3>
                    <div class="quick-reference-grid">
                        <div class="quick-ref-item">
                            <div class="label">HbA1c Goal</div>
                            <div class="value">&lt; 7% (most adults)</div>
                        </div>
                        <div class="quick-ref-item">
                            <div class="label">Fasting Glucose</div>
                            <div class="value">80-130 mg/dL</div>
                        </div>
                        <div class="quick-ref-item">
                            <div class="label">Postprandial (2hr)</div>
                            <div class="value">&lt; 180 mg/dL</div>
                        </div>
                        <div class="quick-ref-item">
                            <div class="label">Hypoglycemia Threshold</div>
                            <div class="value">&lt; 70 mg/dL</div>
                        </div>
                    </div>
                </div>

                <div class="info-box nclex-tip">
                    <div class="info-box-header">
                        <i class="fas fa-graduation-cap"></i> Key Concept
                    </div>
                    <p><strong>HbA1c reflects average blood glucose over the past 2-3 months.</strong> It correlates with the lifespan of red blood cells. An HbA1c of 7% corresponds to an average glucose of approximately 154 mg/dL. Conditions that affect RBC turnover (hemolytic anemia, blood transfusions, sickle cell disease) can give falsely low or high results.</p>
                </div>

                <div class="bottom-line"><strong>Bottom Line:</strong> Type 1 = no insulin production, always needs insulin. Type 2 = insulin resistance, starts with metformin, may progress to needing insulin. Target HbA1c &lt; 7% for most adults.</div>
            </section>

            <!-- ============================================ -->
            <!-- Section 2: Insulin Types -->
            <!-- ============================================ -->
            <section class="guide-section" id="insulin-types">
                <h2><span class="section-icon"><i class="fas fa-syringe"></i></span> Insulin Types & Administration</h2>

                <p>Insulin is the cornerstone of Type 1 diabetes management and is often needed in advanced Type 2 diabetes. Knowing the onset, peak, and duration of each type is critical for preventing hypoglycemia and maintaining glucose control.</p>

                <div class="guide-table-wrapper">
                    <table class="guide-table">
                        <thead>
                            <tr>
                                <th>Category</th>
                                <th>Generic (Brand)</th>
                                <th>Onset</th>
                                <th>Peak</th>
                                <th>Duration</th>
                                <th>Key Point</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>Rapid-Acting</strong></td>
                                <td>Lispro (Humalog), Aspart (NovoLog), Glulisine (Apidra)</td>
                                <td>10-15 min</td>
                                <td>1-2 hr</td>
                                <td>3-5 hr</td>
                                <td>Give with meals (or within 15 min)</td>
                            </tr>
                            <tr>
                                <td><strong>Short-Acting</strong></td>
                                <td>Regular insulin (Humulin R, Novolin R)</td>
                                <td>30-60 min</td>
                                <td>2-4 hr</td>
                                <td>6-8 hr</td>
                                <td>Give 30 min before meals. Only insulin for IV use.</td>
                            </tr>
                            <tr>
                                <td><strong>Intermediate</strong></td>
                                <td>NPH (Humulin N, Novolin N)</td>
                                <td>1-2 hr</td>
                                <td>4-12 hr</td>
                                <td>18-24 hr</td>
                                <td>Cloudy. Roll gently, never shake. Never give IV.</td>
                            </tr>
                            <tr>
                                <td><strong>Long-Acting</strong></td>
                                <td>Glargine (Lantus, Basaglar), Detemir (Levemir)</td>
                                <td>1-2 hr</td>
                                <td>No peak (flat)</td>
                                <td>24 hr</td>
                                <td>Give once daily, same time. Never mix with other insulins.</td>
                            </tr>
                            <tr>
                                <td><strong>Ultra Long-Acting</strong></td>
                                <td>Degludec (Tresiba)</td>
                                <td>1 hr</td>
                                <td>No peak</td>
                                <td>42+ hr</td>
                                <td>Flexible dosing time. Very stable basal coverage.</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="info-box mnemonic">
                    <div class="info-box-header">
                        <i class="fas fa-brain"></i> Memory Aid: Mixing Insulins
                    </div>
                    <p><strong>"RN" = Regular before NPH</strong></p>
                    <p>When mixing insulins in one syringe, always draw up <strong>clear (Regular) before cloudy (NPH)</strong>. This prevents contaminating the Regular vial with NPH particles.</p>
                    <ul>
                        <li>Inject air into NPH vial first (do NOT withdraw)</li>
                        <li>Inject air into Regular vial, then draw up Regular</li>
                        <li>Then draw up NPH into the same syringe</li>
                    </ul>
                </div>

                <div class="florencebot-tip" id="tip-insulin-peaks">
                    <div class="florencebot-tip-header">
                        <div class="florencebot-tip-icon">
                            <i class="fas fa-lightbulb"></i>
                        </div>
                        <span class="florencebot-tip-label">FlorenceBot Pro Tip</span>
                    </div>
                    <div class="florencebot-tip-title">Peaks = Hypoglycemia Risk</div>
                    <div class="florencebot-tip-content">
                        <strong>The peak is when the insulin is working hardest &mdash; and when hypoglycemia risk is greatest.</strong> Rapid-acting peaks in 1-2 hours (watch right after meals), NPH peaks at 4-12 hours (watch for late afternoon or overnight lows), and long-acting insulins like glargine have no peak (lower hypo risk). Always ensure food is available at peak times. If a patient on NPH skips lunch, they are at high risk for hypoglycemia in the afternoon.
                    </div>
                </div>

                <h3>Insulin Administration Nursing Considerations</h3>

                <div class="interventions-list">
                    <h4><i class="fas fa-user-nurse"></i> Critical Insulin Safety Points</h4>

                    <div class="intervention-item">
                        <div class="intervention-number">1</div>
                        <div class="intervention-content">
                            <h5>Always Verify Blood Glucose Before Administration</h5>
                            <p>Check BG before giving insulin. Hold and notify provider if BG is below the facility's threshold (commonly &lt; 70 mg/dL). Follow sliding scale parameters carefully.</p>
                        </div>
                    </div>

                    <div class="intervention-item">
                        <div class="intervention-number">2</div>
                        <div class="intervention-content">
                            <h5>Rotate Injection Sites</h5>
                            <p>Use abdomen (fastest absorption), upper arms, thighs, or buttocks. Rotate within the same region for consistency. Avoid injecting into areas that will be exercised (increases absorption rate).</p>
                        </div>
                    </div>

                    <div class="intervention-item">
                        <div class="intervention-number">3</div>
                        <div class="intervention-content">
                            <h5>Storage and Handling</h5>
                            <p>Unopened insulin: refrigerate (36-46&deg;F). In-use vials/pens: room temperature for 28 days (check specific product). Never freeze insulin. Discard if discolored, clumped, or expired.</p>
                        </div>
                    </div>

                    <div class="intervention-item">
                        <div class="intervention-number">4</div>
                        <div class="intervention-content">
                            <h5>High-Alert Medication</h5>
                            <p>Insulin is an ISMP high-alert medication. Require independent double-check per facility policy. Use insulin-specific syringes only. Never abbreviate "units" as "U" (can be misread as "0").</p>
                        </div>
                    </div>
                </div>

                <div class="info-box warning">
                    <div class="info-box-header">
                        <i class="fas fa-exclamation-triangle"></i> Safety Alert: Sound-Alike Insulins
                    </div>
                    <p><strong>Humalog vs. Humulin</strong> and <strong>NovoLog vs. Novolin</strong> are commonly confused. Humalog and NovoLog are rapid-acting. Humulin and Novolin can be Regular (R) or NPH (N). Always verify the exact insulin type, not just the brand.</p>
                </div>

                <div class="bottom-line"><strong>Bottom Line:</strong> Know onset/peak/duration for each insulin type. Regular is the only insulin given IV. Never mix glargine or detemir. Draw Regular before NPH ("RN"). Peak time = highest hypoglycemia risk.</div>
            </section>

            <!-- ============================================ -->
            <!-- Section 3: Metformin -->
            <!-- ============================================ -->
            <section class="guide-section" id="metformin">
                <h2><span class="section-icon"><i class="fas fa-prescription-bottle-alt"></i></span> Metformin (Biguanides)</h2>

                <p><strong>Metformin (Glucophage)</strong> is the first-line drug for Type 2 diabetes and one of the most commonly prescribed medications worldwide. It works primarily by decreasing hepatic glucose production and improving insulin sensitivity in peripheral tissues.</p>

                <div class="quick-reference">
                    <h3><i class="fas fa-prescription"></i> Quick Reference: Metformin</h3>
                    <div class="quick-reference-grid">
                        <div class="quick-ref-item">
                            <div class="label">Drug Class</div>
                            <div class="value">Biguanide</div>
                        </div>
                        <div class="quick-ref-item">
                            <div class="label">Route</div>
                            <div class="value">PO (with meals)</div>
                        </div>
                        <div class="quick-ref-item">
                            <div class="label">Typical Starting Dose</div>
                            <div class="value">500 mg BID or 850 mg daily</div>
                        </div>
                        <div class="quick-ref-item">
                            <div class="label">Max Dose</div>
                            <div class="value">2,550 mg/day</div>
                        </div>
                    </div>
                </div>

                <h3>Mechanism of Action</h3>
                <ul>
                    <li><strong>Decreases hepatic glucose production</strong> (primary mechanism)</li>
                    <li>Increases insulin sensitivity in muscle and fat tissue</li>
                    <li>Decreases intestinal absorption of glucose</li>
                    <li>Does NOT stimulate insulin secretion from beta cells</li>
                </ul>

                <h3>Key Advantages</h3>
                <ul>
                    <li><strong>No hypoglycemia</strong> when used alone (does not increase insulin secretion)</li>
                    <li><strong>Weight neutral or mild weight loss</strong> (unlike sulfonylureas/insulin)</li>
                    <li>Proven cardiovascular benefit</li>
                    <li>Inexpensive and well-established safety profile</li>
                </ul>

                <div class="florencebot-tip" id="tip-metformin-gi">
                    <div class="florencebot-tip-header">
                        <div class="florencebot-tip-icon">
                            <i class="fas fa-lightbulb"></i>
                        </div>
                        <span class="florencebot-tip-label">FlorenceBot Pro Tip</span>
                    </div>
                    <div class="florencebot-tip-title">Metformin GI Side Effects</div>
                    <div class="florencebot-tip-content">
                        <strong>GI side effects are the #1 reason patients stop metformin.</strong> Nausea, diarrhea, and abdominal cramping are common when starting therapy. Teach patients to take it <strong>with food</strong> and to start at a low dose with gradual titration. The extended-release (ER) formulation causes significantly fewer GI side effects and can be a good alternative for patients who can't tolerate immediate-release.
                    </div>
                </div>

                <div class="info-box warning">
                    <div class="info-box-header">
                        <i class="fas fa-exclamation-triangle"></i> Critical: Lactic Acidosis Risk
                    </div>
                    <p><strong>Lactic acidosis is rare but life-threatening.</strong> Know these contraindications and precautions:</p>
                    <ul>
                        <li><strong>Hold before IV contrast dye procedures</strong> (hold 48 hours before and after; restart only after renal function confirmed stable)</li>
                        <li><strong>Contraindicated if eGFR &lt; 30 mL/min</strong> (severe renal impairment)</li>
                        <li>Use caution with hepatic impairment, heart failure, excessive alcohol use</li>
                        <li><strong>Signs of lactic acidosis:</strong> malaise, myalgia, respiratory distress, unusual fatigue, abdominal pain</li>
                    </ul>
                </div>

                <div class="info-box tip">
                    <div class="info-box-header">
                        <i class="fas fa-check-circle"></i> Patient Teaching: Metformin
                    </div>
                    <ul>
                        <li>Take with meals to reduce GI side effects</li>
                        <li>Avoid excessive alcohol (increases lactic acidosis risk)</li>
                        <li>Report symptoms of lactic acidosis: unusual muscle pain, difficulty breathing, unusual fatigue</li>
                        <li>May cause vitamin B12 deficiency with long-term use &mdash; monitor levels</li>
                        <li>Inform all providers you take metformin before any imaging with contrast dye</li>
                    </ul>
                </div>

                <div class="bottom-line"><strong>Bottom Line:</strong> Metformin is first-line for T2DM. No hypoglycemia when used alone. Hold for contrast dye procedures. Contraindicated in severe renal disease. Take with food to minimize GI effects.</div>
            </section>

            <!-- ============================================ -->
            <!-- Section 4: Sulfonylureas & Meglitinides -->
            <!-- ============================================ -->
            <section class="guide-section" id="sulfonylureas-meglitinides">
                <h2><span class="section-icon"><i class="fas fa-capsules"></i></span> Sulfonylureas & Meglitinides</h2>

                <p>Both of these classes work by <strong>stimulating insulin secretion from pancreatic beta cells</strong>. Because they increase insulin release regardless of glucose levels, both carry a risk of hypoglycemia.</p>

                <h3>Sulfonylureas</h3>

                <div class="guide-table-wrapper">
                    <table class="guide-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Generation</th>
                                <th>Dosing</th>
                                <th>Key Notes</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>Glipizide</strong> (Glucotrol)</td>
                                <td>2nd</td>
                                <td>5-20 mg/day, give 30 min before meals</td>
                                <td>Shorter acting, preferred in elderly</td>
                            </tr>
                            <tr>
                                <td><strong>Glyburide</strong> (DiaBeta, Micronase)</td>
                                <td>2nd</td>
                                <td>2.5-20 mg/day</td>
                                <td>Longer acting, higher hypo risk. Avoid in renal impairment.</td>
                            </tr>
                            <tr>
                                <td><strong>Glimepiride</strong> (Amaryl)</td>
                                <td>2nd</td>
                                <td>1-8 mg/day</td>
                                <td>Once daily dosing. Lower hypo risk than glyburide.</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <h4>Mechanism of Action</h4>
                <p>Sulfonylureas bind to receptors on pancreatic beta cells, closing potassium channels and triggering insulin release. They require functioning beta cells to work (ineffective in Type 1 diabetes).</p>

                <div class="info-box warning">
                    <div class="info-box-header">
                        <i class="fas fa-exclamation-triangle"></i> Side Effects & Warnings
                    </div>
                    <ul>
                        <li><strong>Hypoglycemia</strong> (most significant adverse effect &mdash; especially with glyburide, in elderly, or with skipped meals)</li>
                        <li><strong>Weight gain</strong> (insulin secretion promotes fat storage)</li>
                        <li>Disulfiram-like reaction with alcohol (flushing, nausea)</li>
                        <li>Cross-allergy with sulfa drugs (use with caution in sulfa-allergic patients)</li>
                    </ul>
                </div>

                <h3>Meglitinides</h3>

                <div class="guide-table-wrapper">
                    <table class="guide-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Dosing</th>
                                <th>Key Notes</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>Repaglinide</strong> (Prandin)</td>
                                <td>0.5-4 mg before each meal</td>
                                <td>Take within 30 min of meals. Skip dose if skip meal.</td>
                            </tr>
                            <tr>
                                <td><strong>Nateglinide</strong> (Starlix)</td>
                                <td>60-120 mg before meals</td>
                                <td>Faster onset, shorter duration than sulfonylureas.</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <p>Meglitinides have a similar mechanism to sulfonylureas but act faster and for a shorter duration. They target <strong>postprandial glucose spikes</strong> and are dosed with meals. If a meal is skipped, the dose is skipped.</p>

                <div class="florencebot-tip" id="tip-sulfonylurea-hypo">
                    <div class="florencebot-tip-header">
                        <div class="florencebot-tip-icon">
                            <i class="fas fa-lightbulb"></i>
                        </div>
                        <span class="florencebot-tip-label">FlorenceBot Pro Tip</span>
                    </div>
                    <div class="florencebot-tip-title">Sulfonylurea Hypoglycemia</div>
                    <div class="florencebot-tip-content">
                        <strong>Sulfonylureas cause hypoglycemia because they stimulate insulin release regardless of blood glucose level.</strong> The risk is highest when patients skip meals, exercise more than usual, drink alcohol, or have renal impairment (drug accumulates). Teach patients to eat regular meals and always carry a fast-acting carbohydrate source. Glyburide has the highest hypoglycemia risk due to its long duration and active metabolites &mdash; glipizide or glimepiride is preferred in the elderly.
                    </div>
                </div>

                <div class="info-box clinical-pearl">
                    <div class="info-box-header">
                        <i class="fas fa-lightbulb"></i> Clinical Pearl: "No Meal, No Pill"
                    </div>
                    <p>For meglitinides (repaglinide, nateglinide), teach patients: <strong>"No meal, no pill."</strong> These drugs are taken before each meal to cover postprandial glucose. If the patient skips a meal, they skip the dose. This flexible dosing makes them useful for patients with irregular eating patterns.</p>
                </div>

                <div class="bottom-line"><strong>Bottom Line:</strong> Sulfonylureas and meglitinides stimulate insulin release from beta cells. Both cause hypoglycemia and weight gain. Sulfonylureas are dosed daily; meglitinides are dosed with meals ("no meal, no pill").</div>
            </section>

            <!-- ============================================ -->
            <!-- Section 5: TZDs & Alpha-Glucosidase Inhibitors -->
            <!-- ============================================ -->
            <section class="guide-section" id="tzds-agi">
                <h2><span class="section-icon"><i class="fas fa-tablets"></i></span> TZDs & Alpha-Glucosidase Inhibitors</h2>

                <h3>Thiazolidinediones (TZDs) &mdash; The "Insulin Sensitizers"</h3>

                <p>TZDs improve insulin sensitivity in muscle and adipose tissue by activating PPARgamma receptors. They do not increase insulin secretion and take 2-4 weeks for full effect.</p>

                <div class="guide-table-wrapper">
                    <table class="guide-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Dosing</th>
                                <th>Key Notes</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>Pioglitazone</strong> (Actos)</td>
                                <td>15-45 mg daily</td>
                                <td>May improve lipid profile. Bladder cancer risk with prolonged use.</td>
                            </tr>
                            <tr>
                                <td><strong>Rosiglitazone</strong> (Avandia)</td>
                                <td>4-8 mg daily</td>
                                <td>Restricted due to cardiovascular concerns. Rarely used.</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="info-box warning">
                    <div class="info-box-header">
                        <i class="fas fa-exclamation-triangle"></i> TZD Warnings
                    </div>
                    <ul>
                        <li><strong>Fluid retention and edema</strong> &mdash; can precipitate or worsen heart failure. <strong>Contraindicated in NYHA Class III-IV heart failure.</strong></li>
                        <li><strong>Weight gain</strong> (fluid retention + fat redistribution)</li>
                        <li><strong>Increased fracture risk</strong> (especially in postmenopausal women)</li>
                        <li><strong>Hepatotoxicity</strong> &mdash; monitor LFTs at baseline and periodically</li>
                        <li>Slow onset of action (2-4 weeks for effect, 8-12 weeks for full effect)</li>
                    </ul>
                </div>

                <h3>Alpha-Glucosidase Inhibitors</h3>

                <p>These drugs slow the breakdown and absorption of complex carbohydrates in the small intestine, reducing postprandial glucose spikes.</p>

                <div class="guide-table-wrapper">
                    <table class="guide-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Dosing</th>
                                <th>Key Notes</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>Acarbose</strong> (Precose)</td>
                                <td>25-100 mg with first bite of each meal</td>
                                <td>Must take with food to work. Monitor LFTs.</td>
                            </tr>
                            <tr>
                                <td><strong>Miglitol</strong> (Glyset)</td>
                                <td>25-100 mg with first bite of each meal</td>
                                <td>Similar to acarbose; better absorbed.</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="info-box clinical-pearl">
                    <div class="info-box-header">
                        <i class="fas fa-lightbulb"></i> Clinical Pearl: Treating Hypoglycemia on AGIs
                    </div>
                    <p><strong>If a patient on an alpha-glucosidase inhibitor becomes hypoglycemic, give GLUCOSE (dextrose) tablets &mdash; not sucrose (table sugar)!</strong> These drugs block the breakdown of complex sugars, so sucrose, juice, and crackers will not be absorbed fast enough. Only pure glucose (dextrose) will work because it doesn't need to be broken down.</p>
                </div>

                <div class="info-box tip">
                    <div class="info-box-header">
                        <i class="fas fa-check-circle"></i> AGI Side Effects & Teaching
                    </div>
                    <ul>
                        <li><strong>GI effects are very common:</strong> flatulence, bloating, abdominal discomfort, diarrhea</li>
                        <li>Start low and titrate slowly to minimize GI symptoms</li>
                        <li>Take with the <strong>first bite</strong> of each meal (must be present with food to work)</li>
                        <li>Minimal hypoglycemia risk when used alone</li>
                    </ul>
                </div>

                <div class="bottom-line"><strong>Bottom Line:</strong> TZDs improve insulin sensitivity but cause fluid retention (contraindicated in severe HF) and fracture risk. AGIs slow carb absorption &mdash; treat hypoglycemia with glucose tablets, NOT regular sugar.</div>
            </section>

            <!-- ============================================ -->
            <!-- Section 6: DPP-4 & GLP-1 -->
            <!-- ============================================ -->
            <section class="guide-section" id="incretin-based">
                <h2><span class="section-icon"><i class="fas fa-vial"></i></span> DPP-4 Inhibitors & GLP-1 Receptor Agonists</h2>

                <p>These two classes are based on the <strong>incretin system</strong>. Incretins (like GLP-1) are gut hormones released after eating that stimulate insulin secretion and suppress glucagon in a glucose-dependent manner. This means they are less likely to cause hypoglycemia.</p>

                <h3>DPP-4 Inhibitors (The "-gliptins")</h3>

                <p>DPP-4 is the enzyme that breaks down incretins. By inhibiting DPP-4, these drugs prolong the action of natural GLP-1 and GIP, enhancing glucose-dependent insulin secretion.</p>

                <div class="guide-table-wrapper">
                    <table class="guide-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Dosing</th>
                                <th>Key Notes</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>Sitagliptin</strong> (Januvia)</td>
                                <td>100 mg daily</td>
                                <td>Dose adjust for renal impairment</td>
                            </tr>
                            <tr>
                                <td><strong>Saxagliptin</strong> (Onglyza)</td>
                                <td>2.5-5 mg daily</td>
                                <td>Heart failure risk &mdash; use with caution</td>
                            </tr>
                            <tr>
                                <td><strong>Linagliptin</strong> (Tradjenta)</td>
                                <td>5 mg daily</td>
                                <td>No renal dose adjustment needed (biliary excretion)</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="info-box tip">
                    <div class="info-box-header">
                        <i class="fas fa-check-circle"></i> DPP-4 Inhibitor Advantages
                    </div>
                    <ul>
                        <li><strong>Weight neutral</strong> (no significant weight gain or loss)</li>
                        <li><strong>Low hypoglycemia risk</strong> (glucose-dependent mechanism)</li>
                        <li>Well tolerated with few side effects</li>
                        <li>Simple once-daily oral dosing</li>
                        <li>Watch for: joint pain (arthralgia), rare pancreatitis risk, upper respiratory infection symptoms</li>
                    </ul>
                </div>

                <h3>GLP-1 Receptor Agonists (The "-tide" Drugs)</h3>

                <p>GLP-1 agonists mimic the GLP-1 incretin hormone at pharmacologic levels, providing much stronger effects than DPP-4 inhibitors. They are injectable (except oral semaglutide) and have significant benefits beyond glucose control.</p>

                <div class="guide-table-wrapper">
                    <table class="guide-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Route/Frequency</th>
                                <th>Key Notes</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>Liraglutide</strong> (Victoza)</td>
                                <td>SubQ daily</td>
                                <td>Also approved for cardiovascular risk reduction</td>
                            </tr>
                            <tr>
                                <td><strong>Semaglutide</strong> (Ozempic)</td>
                                <td>SubQ weekly</td>
                                <td>Significant weight loss. Also available as oral (Rybelsus).</td>
                            </tr>
                            <tr>
                                <td><strong>Dulaglutide</strong> (Trulicity)</td>
                                <td>SubQ weekly</td>
                                <td>CV benefit demonstrated. Single-use pen.</td>
                            </tr>
                            <tr>
                                <td><strong>Exenatide</strong> (Byetta, Bydureon)</td>
                                <td>SubQ twice daily or weekly (ER)</td>
                                <td>First GLP-1 approved. Give Byetta within 60 min before meals.</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="info-box warning">
                    <div class="info-box-header">
                        <i class="fas fa-exclamation-triangle"></i> GLP-1 Agonist Warnings
                    </div>
                    <ul>
                        <li><strong>Black box warning: thyroid C-cell tumors</strong> (medullary thyroid carcinoma in animal studies). <strong>Contraindicated in patients with personal or family history of medullary thyroid cancer or MEN 2 syndrome.</strong></li>
                        <li><strong>GI side effects:</strong> nausea, vomiting, diarrhea (most common, usually improve over time)</li>
                        <li><strong>Pancreatitis risk:</strong> Teach patients to report severe, persistent abdominal pain</li>
                        <li>Delayed gastric emptying &mdash; caution with gastroparesis</li>
                    </ul>
                </div>

                <div class="florencebot-tip" id="tip-glp1-benefits">
                    <div class="florencebot-tip-header">
                        <div class="florencebot-tip-icon">
                            <i class="fas fa-lightbulb"></i>
                        </div>
                        <span class="florencebot-tip-label">FlorenceBot Pro Tip</span>
                    </div>
                    <div class="florencebot-tip-title">GLP-1 Triple Benefit</div>
                    <div class="florencebot-tip-content">
                        <strong>GLP-1 agonists offer three key benefits beyond glucose lowering:</strong> (1) <strong>Weight loss</strong> &mdash; they slow gastric emptying and reduce appetite, making them especially beneficial for overweight T2DM patients; (2) <strong>Cardiovascular protection</strong> &mdash; liraglutide, semaglutide, and dulaglutide have proven CV benefit; (3) <strong>Low hypoglycemia risk</strong> &mdash; they only stimulate insulin when glucose is elevated. The main trade-off is GI side effects (nausea) and the thyroid C-cell tumor black box warning.
                    </div>
                </div>

                <div class="info-box nclex-tip">
                    <div class="info-box-header">
                        <i class="fas fa-graduation-cap"></i> DPP-4 vs. GLP-1: How to Remember the Difference
                    </div>
                    <p><strong>DPP-4 inhibitors</strong> = "protect" your own incretins (oral, mild effect, weight neutral)</p>
                    <p><strong>GLP-1 agonists</strong> = "replace" with a superpowered version (injectable, stronger effect, weight loss)</p>
                    <p>Do NOT combine DPP-4 inhibitors with GLP-1 agonists &mdash; they work on the same pathway and there is no added benefit.</p>
                </div>

                <div class="bottom-line"><strong>Bottom Line:</strong> DPP-4 inhibitors ("-gliptins") are well-tolerated oral agents with low hypo risk. GLP-1 agonists ("-tides") are injectable, promote weight loss, and have CV benefits but carry a black box warning for thyroid C-cell tumors. Don't combine the two classes.</div>
            </section>

            <!-- ============================================ -->
            <!-- Section 7: SGLT2 Inhibitors -->
            <!-- ============================================ -->
            <section class="guide-section" id="sglt2">
                <h2><span class="section-icon"><i class="fas fa-tint"></i></span> SGLT2 Inhibitors</h2>

                <p><strong>Sodium-glucose co-transporter 2 (SGLT2) inhibitors</strong> represent a unique class that works in the kidneys rather than the pancreas. They block glucose reabsorption in the proximal tubule, causing excess glucose to be excreted in the urine (glycosuria).</p>

                <div class="guide-table-wrapper">
                    <table class="guide-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Dosing</th>
                                <th>Key Notes</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>Empagliflozin</strong> (Jardiance)</td>
                                <td>10-25 mg daily</td>
                                <td>Proven CV and renal benefits. Also approved for HF.</td>
                            </tr>
                            <tr>
                                <td><strong>Dapagliflozin</strong> (Farxiga)</td>
                                <td>5-10 mg daily</td>
                                <td>Approved for HF and CKD regardless of diabetes status.</td>
                            </tr>
                            <tr>
                                <td><strong>Canagliflozin</strong> (Invokana)</td>
                                <td>100-300 mg daily</td>
                                <td>Associated with increased amputation risk (assess feet). CV benefit.</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="info-box mnemonic">
                    <div class="info-box-header">
                        <i class="fas fa-brain"></i> Memory Aid: SGLT2 = "Sugar Goes to Lavatory Too"
                    </div>
                    <p>SGLT2 inhibitors cause the kidneys to dump glucose into the urine. This glucose-rich urine creates a perfect environment for infections. Remember: <strong>Sugar Goes to Lavatory Too</strong> &mdash; and that sugar feeds yeast and bacteria, causing UTIs and genital infections.</p>
                </div>

                <div class="florencebot-tip" id="tip-sglt2-dka">
                    <div class="florencebot-tip-header">
                        <div class="florencebot-tip-icon">
                            <i class="fas fa-lightbulb"></i>
                        </div>
                        <span class="florencebot-tip-label">FlorenceBot Pro Tip</span>
                    </div>
                    <div class="florencebot-tip-title">Euglycemic DKA Warning</div>
                    <div class="florencebot-tip-content">
                        <strong>SGLT2 inhibitors can cause DKA even with NORMAL blood glucose levels (euglycemic DKA).</strong> This is a dangerous trap because providers may not suspect DKA when the glucose reading looks normal. If a patient on an SGLT2 inhibitor presents with nausea, vomiting, abdominal pain, or fruity breath, check for ketones even if blood glucose is below 250 mg/dL. Hold SGLT2 inhibitors before surgery (at least 3-4 days) and during acute illness.
                    </div>
                </div>

                <div class="info-box warning">
                    <div class="info-box-header">
                        <i class="fas fa-exclamation-triangle"></i> SGLT2 Side Effects & Warnings
                    </div>
                    <ul>
                        <li><strong>Genital yeast infections</strong> (glycosuria feeds candida &mdash; more common in women)</li>
                        <li><strong>Urinary tract infections</strong></li>
                        <li><strong>Euglycemic DKA</strong> (DKA with normal glucose &mdash; check ketones if symptomatic)</li>
                        <li><strong>Hypotension/dehydration</strong> (osmotic diuresis) &mdash; monitor BP, encourage hydration</li>
                        <li><strong>Fournier's gangrene</strong> (rare necrotizing fasciitis of perineum &mdash; teach patients to report genital/perineal pain or tenderness)</li>
                        <li>Canagliflozin: increased risk of lower limb amputations (assess feet regularly)</li>
                    </ul>
                </div>

                <div class="info-box tip">
                    <div class="info-box-header">
                        <i class="fas fa-check-circle"></i> SGLT2 Benefits Beyond Glucose
                    </div>
                    <ul>
                        <li><strong>Cardiovascular protection</strong> (reduced hospitalizations for heart failure)</li>
                        <li><strong>Renal protection</strong> (slows CKD progression)</li>
                        <li><strong>Weight loss</strong> (losing calories through glycosuria)</li>
                        <li><strong>Blood pressure reduction</strong> (mild diuretic effect)</li>
                        <li>Low hypoglycemia risk when used alone</li>
                    </ul>
                </div>

                <div class="bottom-line"><strong>Bottom Line:</strong> SGLT2 inhibitors ("-gliflozin") work in the kidneys to dump glucose in urine. Benefits include weight loss, CV protection, and renal protection. Watch for genital infections, UTIs, euglycemic DKA, and dehydration. Hold before surgery.</div>
            </section>

            <!-- ============================================ -->
            <!-- Section 8: Hypoglycemia Management -->
            <!-- ============================================ -->
            <section class="guide-section" id="hypoglycemia">
                <h2><span class="section-icon"><i class="fas fa-exclamation-circle"></i></span> Hypoglycemia Management</h2>

                <p>Hypoglycemia (blood glucose &lt; 70 mg/dL) is the most common and dangerous acute complication of diabetes medication therapy. Rapid recognition and treatment are critical to prevent seizures, loss of consciousness, and death.</p>

                <h3>Signs and Symptoms</h3>

                <div class="comparison-grid">
                    <div class="comparison-card rapid">
                        <div class="comparison-card-header">
                            <i class="fas fa-bolt"></i> Mild-Moderate (Adrenergic)
                        </div>
                        <div class="comparison-card-body">
                            <ul>
                                <li><i class="fas fa-check"></i> <strong>Tremors/shakiness</strong></li>
                                <li><i class="fas fa-check"></i> <strong>Sweating</strong> (diaphoresis)</li>
                                <li><i class="fas fa-check"></i> <strong>Tachycardia</strong> (rapid heart rate)</li>
                                <li><i class="fas fa-check"></i> <strong>Hunger</strong></li>
                                <li><i class="fas fa-check"></i> Anxiety, irritability</li>
                                <li><i class="fas fa-check"></i> Pallor, tingling</li>
                            </ul>
                        </div>
                    </div>

                    <div class="comparison-card long">
                        <div class="comparison-card-header">
                            <i class="fas fa-brain"></i> Severe (Neuroglycopenic)
                        </div>
                        <div class="comparison-card-body">
                            <ul>
                                <li><i class="fas fa-check"></i> <strong>Confusion</strong></li>
                                <li><i class="fas fa-check"></i> <strong>Slurred speech</strong></li>
                                <li><i class="fas fa-check"></i> <strong>Seizures</strong></li>
                                <li><i class="fas fa-check"></i> <strong>Loss of consciousness</strong></li>
                                <li><i class="fas fa-check"></i> Behavioral changes</li>
                                <li><i class="fas fa-check"></i> Visual disturbances</li>
                            </ul>
                        </div>
                    </div>
                </div>

                <div class="florencebot-tip" id="tip-rule-of-15">
                    <div class="florencebot-tip-header">
                        <div class="florencebot-tip-icon">
                            <i class="fas fa-lightbulb"></i>
                        </div>
                        <span class="florencebot-tip-label">FlorenceBot Pro Tip</span>
                    </div>
                    <div class="florencebot-tip-title">Rule of 15</div>
                    <div class="florencebot-tip-content">
                        <strong>The Rule of 15 is the standard protocol for conscious hypoglycemia:</strong> Give <strong>15 grams</strong> of fast-acting carbohydrate, wait <strong>15 minutes</strong>, recheck blood glucose. Repeat if still below 70 mg/dL. Examples of 15g fast-acting carbs: 4 oz (1/2 cup) juice or regular soda, 3-4 glucose tablets, 1 tablespoon of honey or sugar. Once BG normalizes, follow with a complex carb and protein snack to prevent rebound. If the patient is <strong>unconscious</strong>, never give anything by mouth &mdash; administer IV dextrose (D50 in adults) or IM glucagon.
                    </div>
                </div>

                <div class="interventions-list">
                    <h4><i class="fas fa-first-aid"></i> Hypoglycemia Treatment Protocol</h4>

                    <div class="intervention-item">
                        <div class="intervention-number">1</div>
                        <div class="intervention-content">
                            <h5>Conscious Patient: Rule of 15</h5>
                            <p>Give 15g fast-acting carbohydrate (4 oz juice, 3-4 glucose tabs). Recheck in 15 minutes. Repeat if BG still &lt; 70 mg/dL. Follow with complex carb + protein snack.</p>
                        </div>
                    </div>

                    <div class="intervention-item">
                        <div class="intervention-number">2</div>
                        <div class="intervention-content">
                            <h5>Unconscious Patient: IV Dextrose or Glucagon</h5>
                            <p><strong>Never give oral glucose to an unconscious patient</strong> (aspiration risk). Give IV dextrose 50% (D50W) 25-50 mL push. If no IV access, give IM glucagon 1 mg. Position on side to protect airway.</p>
                        </div>
                    </div>

                    <div class="intervention-item">
                        <div class="intervention-number">3</div>
                        <div class="intervention-content">
                            <h5>Post-Recovery</h5>
                            <p>Investigate the cause (skipped meal? too much insulin? increased activity?). Continue monitoring BG every 15-30 minutes until stable. Document and report the event. Educate patient on prevention.</p>
                        </div>
                    </div>
                </div>

                <div class="info-box warning">
                    <div class="info-box-header">
                        <i class="fas fa-exclamation-triangle"></i> Critical Alert: Hypoglycemia Unawareness
                    </div>
                    <p><strong>Some patients (especially those with long-standing diabetes or on beta-blockers) lose the early adrenergic warning signs</strong> (no sweating, no tremors, no tachycardia). They may progress directly to severe neuroglycopenic symptoms (confusion, seizures, unconsciousness). These patients need more frequent glucose monitoring and higher glucose targets.</p>
                </div>

                <div class="bottom-line"><strong>Bottom Line:</strong> Rule of 15 for conscious hypo. IV D50 or IM glucagon for unconscious patients &mdash; never give oral glucose. Beta-blockers can mask hypoglycemia symptoms. Always investigate the cause after treatment.</div>
            </section>

            <!-- ============================================ -->
            <!-- Section 9: Comparison -->
            <!-- ============================================ -->
            <section class="guide-section" id="comparison">
                <h2><span class="section-icon"><i class="fas fa-th-list"></i></span> Drug Class Comparison</h2>

                <p>This comprehensive comparison table helps you quickly compare all diabetes medication classes side by side.</p>

                <div class="guide-table-wrapper">
                    <table class="guide-table">
                        <thead>
                            <tr>
                                <th>Drug Class</th>
                                <th>Mechanism</th>
                                <th>Hypo Risk?</th>
                                <th>Weight Effect</th>
                                <th>Route</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>Insulin</strong></td>
                                <td>Replaces endogenous insulin</td>
                                <td>YES (highest)</td>
                                <td>Weight gain</td>
                                <td>SubQ / IV (Regular only)</td>
                            </tr>
                            <tr>
                                <td><strong>Metformin</strong></td>
                                <td>Decreases hepatic glucose output</td>
                                <td>No (alone)</td>
                                <td>Neutral / slight loss</td>
                                <td>PO</td>
                            </tr>
                            <tr>
                                <td><strong>Sulfonylureas</strong></td>
                                <td>Stimulates insulin secretion</td>
                                <td>YES</td>
                                <td>Weight gain</td>
                                <td>PO</td>
                            </tr>
                            <tr>
                                <td><strong>Meglitinides</strong></td>
                                <td>Stimulates rapid insulin release</td>
                                <td>YES (less than SU)</td>
                                <td>Weight gain</td>
                                <td>PO (with meals)</td>
                            </tr>
                            <tr>
                                <td><strong>TZDs</strong></td>
                                <td>Increases insulin sensitivity</td>
                                <td>No (alone)</td>
                                <td>Weight gain</td>
                                <td>PO</td>
                            </tr>
                            <tr>
                                <td><strong>AGIs</strong></td>
                                <td>Slows carbohydrate absorption</td>
                                <td>No (alone)</td>
                                <td>Neutral</td>
                                <td>PO (with meals)</td>
                            </tr>
                            <tr>
                                <td><strong>DPP-4 Inhibitors</strong></td>
                                <td>Prolongs natural incretins</td>
                                <td>No (alone)</td>
                                <td>Neutral</td>
                                <td>PO</td>
                            </tr>
                            <tr>
                                <td><strong>GLP-1 Agonists</strong></td>
                                <td>Mimics GLP-1 incretin</td>
                                <td>No (alone)</td>
                                <td>Weight loss</td>
                                <td>SubQ (most) / PO (semaglutide)</td>
                            </tr>
                            <tr>
                                <td><strong>SGLT2 Inhibitors</strong></td>
                                <td>Blocks renal glucose reabsorption</td>
                                <td>No (alone)</td>
                                <td>Weight loss</td>
                                <td>PO</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="info-box mnemonic">
                    <div class="info-box-header">
                        <i class="fas fa-brain"></i> Memory Aid: Which Drugs Cause Hypoglycemia?
                    </div>
                    <p><strong>Only three classes cause hypoglycemia when used alone:</strong></p>
                    <ul>
                        <li><strong>I</strong>nsulin</li>
                        <li><strong>S</strong>ulfonylureas</li>
                        <li><strong>M</strong>eglitinides</li>
                    </ul>
                    <p>Remember: <strong>"ISM"</strong> &mdash; these three <strong>I</strong>ncrease in<strong>S</strong>ulin secretion or replace it, so they cause hypo regardless of glucose levels. All other classes are glucose-dependent or work through other <strong>M</strong>echanisms.</p>
                </div>

                <div class="florencebot-tip" id="tip-which-cause-hypo">
                    <div class="florencebot-tip-header">
                        <div class="florencebot-tip-icon">
                            <i class="fas fa-lightbulb"></i>
                        </div>
                        <span class="florencebot-tip-label">FlorenceBot Pro Tip</span>
                    </div>
                    <div class="florencebot-tip-title">Hypo Risk Drugs</div>
                    <div class="florencebot-tip-content">
                        <strong>Most diabetes medications do NOT cause hypoglycemia when used alone.</strong> Only insulin, sulfonylureas, and meglitinides directly stimulate insulin release regardless of blood glucose level. All other classes (metformin, TZDs, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors, AGIs) work through glucose-dependent mechanisms. However, ANY drug can contribute to hypoglycemia when combined with insulin or a sulfonylurea, so always assess the full medication list.
                    </div>
                </div>

                <h3>Drug Interactions to Watch</h3>

                <div class="interventions-list">
                    <h4><i class="fas fa-exclamation-circle"></i> High-Yield Drug Interactions</h4>

                    <div class="intervention-item">
                        <div class="intervention-number">1</div>
                        <div class="intervention-content">
                            <h5>Beta-Blockers + Insulin/Sulfonylureas</h5>
                            <p>Beta-blockers mask tachycardia and tremors (adrenergic symptoms of hypoglycemia). Sweating is preserved. Patients may not recognize they are hypoglycemic until severe neuroglycopenic symptoms appear.</p>
                        </div>
                    </div>

                    <div class="intervention-item">
                        <div class="intervention-number">2</div>
                        <div class="intervention-content">
                            <h5>Corticosteroids + All Diabetes Meds</h5>
                            <p>Corticosteroids cause hyperglycemia by increasing insulin resistance and gluconeogenesis. Patients on diabetes medications may need dose increases when starting steroids. Monitor glucose closely.</p>
                        </div>
                    </div>

                    <div class="intervention-item">
                        <div class="intervention-number">3</div>
                        <div class="intervention-content">
                            <h5>Alcohol + Metformin or Sulfonylureas</h5>
                            <p>Alcohol increases lactic acidosis risk with metformin and increases hypoglycemia risk with sulfonylureas (inhibits gluconeogenesis). Advise moderation and never drink on an empty stomach.</p>
                        </div>
                    </div>

                    <div class="intervention-item">
                        <div class="intervention-number">4</div>
                        <div class="intervention-content">
                            <h5>ACE Inhibitors/ARBs + SGLT2 Inhibitors</h5>
                            <p>Both classes can lower blood pressure and affect renal function. Monitor blood pressure and kidney function (BUN, creatinine, eGFR) when used together.</p>
                        </div>
                    </div>
                </div>

                <div class="bottom-line"><strong>Bottom Line:</strong> Only insulin, sulfonylureas, and meglitinides cause hypoglycemia alone. Beta-blockers mask hypo symptoms. Steroids raise glucose. Always review the full med list for interactions.</div>
            </section>

            <!-- ============================================ -->
            <!-- Section 10: Pediatric Considerations -->
            <!-- ============================================ -->
            <section class="guide-section" id="pediatric">
                <h2><span class="section-icon"><i class="fas fa-baby"></i></span> Pediatric Considerations</h2>

                <p>Diabetes medication management in children and adolescents requires special considerations related to growth, development, and unique physiological factors.</p>

                <div class="info-box pediatric">
                    <div class="info-box-header">
                        <i class="fas fa-baby"></i> Type 1 Diabetes in Children
                    </div>
                    <p><strong>Type 1 is the most common form of diabetes in children.</strong> Key pediatric considerations:</p>
                    <ul>
                        <li><strong>Insulin doses are weight-based</strong> (typically 0.5-1.0 units/kg/day total, adjusted by growth and puberty)</li>
                        <li>Insulin pumps and continuous glucose monitors (CGMs) are increasingly standard of care</li>
                        <li>Hypoglycemia may present differently: irritability, behavioral changes, difficulty concentrating in school</li>
                        <li>Young children cannot reliably report symptoms &mdash; educate parents and school staff on recognition</li>
                        <li>Adolescents in puberty need higher insulin doses due to growth hormone and sex hormone effects on insulin resistance</li>
                    </ul>
                </div>

                <div class="info-box pediatric">
                    <div class="info-box-header">
                        <i class="fas fa-baby"></i> Type 2 Diabetes in Youth
                    </div>
                    <p><strong>T2DM is rising in children and adolescents, particularly those with obesity.</strong></p>
                    <ul>
                        <li><strong>Metformin is the only oral agent FDA-approved for children</strong> (age 10+)</li>
                        <li>Insulin is the other approved medication for pediatric T2DM</li>
                        <li>Lifestyle modifications (diet, exercise) are emphasized alongside pharmacotherapy</li>
                        <li>GLP-1 agonists (liraglutide) recently approved for adolescents 10+ with T2DM</li>
                        <li>Other oral agents (sulfonylureas, SGLT2 inhibitors) are generally NOT approved for pediatric use</li>
                    </ul>
                </div>

                <div class="info-box pediatric">
                    <div class="info-box-header">
                        <i class="fas fa-baby"></i> School Management & Family Education
                    </div>
                    <ul>
                        <li>Develop a <strong>Diabetes Medical Management Plan (DMMP)</strong> for school</li>
                        <li>School nurses and teachers need training on hypo/hyperglycemia recognition</li>
                        <li>Fast-acting glucose should be available in the classroom, gym, and cafeteria</li>
                        <li>Children should wear medical alert identification</li>
                        <li>Adolescents may struggle with medication adherence due to peer pressure and body image &mdash; provide developmentally appropriate education</li>
                    </ul>
                </div>

                <div class="bottom-line"><strong>Bottom Line:</strong> T1DM is most common in children; insulin is always required with weight-based dosing. For pediatric T2DM, metformin is first-line. Educate families AND school personnel. Hypoglycemia may present as behavioral changes in young children.</div>
            </section>

            <!-- Practice Questions CTA -->
            <section class="practice-questions" id="practice-questions">
                <h2><i class="fas fa-flask"></i> NCLEX Challenge &mdash; Test Your Knowledge</h2>
                <div class="quiz-cta-box">
                    <div class="quiz-cta-icon">
                        <i class="fas fa-clipboard-check"></i>
                    </div>
                    <div class="quiz-cta-content">
                        <h3>Ready to Test Your Knowledge?</h3>
                        <p>10 NCLEX-style questions with detailed rationales covering insulin types, oral antidiabetic drug classes, hypoglycemia management, drug interactions, and nursing considerations. Choose Practice Mode for instant feedback or Exam Mode to simulate test conditions.</p>
                        <div class="quiz-cta-stats">
                            <span><i class="fas fa-question-circle"></i> 10 Questions</span>
                            <span><i class="fas fa-clock"></i> ~15 min</span>
                            <span><i class="fas fa-layer-group"></i> 4 Question Types</span>
                        </div>
                    </div>
                    <a href="quiz/diabetes-medications-quiz.html" class="quiz-cta-button">
                        <i class="fas fa-play"></i> Start Quiz
                    </a>
                </div>
            </section>

            <!-- Key Points Summary -->
            <section class="key-points-summary">
                <h2><i class="fas fa-star"></i> Key Takeaways</h2>
                <div class="key-points-grid">
                    <div class="key-point">
                        <i class="fas fa-syringe"></i>
                        <p><strong>Insulin timing:</strong> Rapid = with meals, Regular = 30 min before, NPH = roll don't shake, Glargine = never mix</p>
                    </div>
                    <div class="key-point">
                        <i class="fas fa-prescription-bottle-alt"></i>
                        <p><strong>Metformin is first-line</strong> for T2DM. Hold for contrast dye. No hypo when used alone.</p>
                    </div>
                    <div class="key-point">
                        <i class="fas fa-exclamation-triangle"></i>
                        <p><strong>Hypo risk drugs:</strong> Insulin, sulfonylureas, meglitinides. All others are low risk when used alone.</p>
                    </div>
                    <div class="key-point">
                        <i class="fas fa-heartbeat"></i>
                        <p><strong>GLP-1 agonists and SGLT2 inhibitors</strong> offer weight loss + cardiovascular protection beyond glucose control.</p>
                    </div>
                    <div class="key-point">
                        <i class="fas fa-first-aid"></i>
                        <p><strong>Rule of 15:</strong> 15g carbs, recheck in 15 min. Unconscious = IV D50 or IM glucagon, never oral.</p>
                    </div>
                    <div class="key-point">
                        <i class="fas fa-vial"></i>
                        <p><strong>Regular before NPH</strong> ("RN"). Only Regular insulin can be given IV. NPH is the only cloudy insulin.</p>
                    </div>
                    <div class="key-point">
                        <i class="fas fa-tint"></i>
                        <p><strong>SGLT2 inhibitors:</strong> Watch for genital infections, UTIs, and euglycemic DKA. Hold before surgery.</p>
                    </div>
                    <div class="key-point">
                        <i class="fas fa-shield-alt"></i>
                        <p><strong>GLP-1 black box:</strong> Thyroid C-cell tumors. Contraindicated in MEN 2 or medullary thyroid cancer history.</p>
                    </div>
                </div>
            </section>

            <!-- Cross-References -->
            <section class="cross-references" id="cross-references">
                <h2><i class="fas fa-book-open"></i> Related Guides in the Library</h2>
                <div class="cross-ref-group">
                    <h3>Before this guide, review:</h3>
                    <ul>
                        <li><span class="coming-soon"><i class="fas fa-clock"></i> Diabetes Type 1 &mdash; Coming Soon</span></li>
                        <li><span class="coming-soon"><i class="fas fa-clock"></i> Diabetes Type 2 &mdash; Coming Soon</span></li>
                    </ul>
                </div>
                <div class="cross-ref-group">
                    <h3>Also relevant:</h3>
                    <ul>
                        <li><span class="coming-soon"><i class="fas fa-clock"></i> Fluid &amp; Electrolytes &mdash; Coming Soon</span></li>
                        <li><a href="heart-failure.html"><i class="fas fa-arrow-right"></i> Heart Failure (SGLT2 inhibitors in HF)</a></li>
                    </ul>
                </div>
            </section>

        </div>

        <!-- Document Footer -->
        <div class="document-footer">
            <img src="../assets/images/the-nursing-collective-logo.webp" alt="The Nursing Collective" class="footer-logo">
            <p class="footer-tagline">Empowering nursing students with evidence-based study resources</p>
            <p class="footer-copyright">&copy; 2026 The Nursing Collective. All rights reserved.</p>
        </div>

    </div>

    <!-- Guide page scripts (external for CSP compliance) -->
    <script src="configs/diabetes-medications-config.js"></script>
    <script src="guide-sidebar.js"></script>
    <script src="guide-script.js"></script>
    <script src="guide-questions.js"></script>
    <script src="../content-gate.js"></script>
</body>
</html>
